Purpose: Diabetic macular edema (DME) is a leading cause of vision loss and blindness.
Introduction
The number of persons with diabetes is growing rapidly and likely to reach 400 million, worldwide, by the year 2030 (NCD Risk Factor Collaboration (NCD-RisC) 2016 ).
An important complication of diabetes is DME, a leading cause of vision loss and blindness (Zhang et al. 2010) in industrialised countries, representing a sight-threatening event for diabetic patients, which is both preventable and, if diagnosed early, treatable.
As DME often affects patients of working age (Klein et al. 1984) , and as the condition leads to an important burden on National Healthcare System (NHS) resources as well as other stateborne expenses (such as invalidity payments for patients with no or very poor vision), this condition should be one of the priorities for the healthcare services, in particular for the public ones.
During the last decade, the availability of effective new technologies, as well as an ever-ageing population, has led to an increased demand on Italian healthcare resources. Governmental spending reviews have aimed at containing healthcare budgets and limiting the diffusion of expensive technologybased healthcare innovations (Radaelli et al. 2014) . As a result, the limited available resources should be preferentially allocated to the most promising healthcare technologies demonstrating the greatest value.
With respect to DME therapies, laser photocoagulation used to be the 'standard' treatment, but in the last 10 years, the introduction of intravitreal delivery of therapeutic agents [anti-vascular endothelial growth factor (VEGF) and corticosteroids] has significantly changed the clinical management of DME.
Clinical trials have demonstrated intravitreal anti-VEGF agents as effective therapy for the treatment of DME (Mitchell et al. 2011; Brown et al. 2013; Korobelnik et al. 2014; Elman et al. 2015; Wells et al. 2015) , leading to their use in this patient population. Corticosteroid intravitreal injections (Degenring et al. 2004; Jonas et al. 2005 ) and more recently, intravitreal corticosteroid implants have also been shown to be effective in the achievement of visual gain, with a reduced frequency of injections (Boyer et al. 2014) .
With regard to the Italian setting, the therapeutic strategies currently available for medical treatment of DME, having followed the Italian national reimbursement process, are: (i) Ranibizumab, which received approval for the treatment of DME in December 2012 (G.U. n. 285 del 06-12-2012); (ii) Aflibercept which received approval in July 2014 (G.U. n. 49 of 28-2-2015), and (iii) the Dexamethasone implant which received approval from August 2015 (G.U. n.251 of 28-10-2015) , but included in the Italian ex Lege 648/96 (GU n.171 of 25-07-2014). It should be noted here that in some European countries, DME can be treated with Bevacizumab, a drug that has not yet approval for use in Italy.
Despite the clinical, social and economic relevance of this therapy area, limited data regarding the overall impact of the DME clinical pathway are available in the literature. An indepth economic evaluation would assist the definition of the mix of effective treatments that should be made available, capable of optimizing the healthcare expenditure devoted to patients with DME, and consequently easing both the societal and the economic burden of pathology.
Moving on from these premises, the aim of this study is to evaluate the potential economic benefits associated with the introduction of additional alternative technologies (innovative scenario) into the Lombardy Regional Healthcare Service, in comparison with the historical scenario consisting of only the repeated administration of intravitreal injections of Ranibizumab (baseline scenario).
To the best of the authors' knowledge, this study is the first such evaluation of the budget impact of the abovementioned intravitreal therapies, from a LRHS point of view, thus paving the way towards an enhanced optimisation of economic resources for the coverage of its citizens' health needs and providing evidence-based solutions useful for decision-making processes.
Methods
A budget impact analysis (BIA) was developed (Mauskopf et al. 2007) , as a methodological approach, to achieve the objective of this study.
The BIA was performed from the LRHS perspective and represented the healthcare expenditure evolution over a 3-year period.
The hospitals involved in the study, whose real-life data were collected during October 2014 to March 2015, were the following: (i) ASST Fatebenefratelli Sacco, Milan; (ii) San Raffaele Hospital, Milan; and (iii) Valduce Hospital, Como.
To build up the model, three phases were developed.
Development of the population entering the model
The number of patients affected by DME, and thus potentially eligible for treatment, was defined. Data derived from the number of Lombardy Region inhabitants, for whom the diabetes and the DME prevalence rates were applied (Diabetic Retinopathy Guidelines, 2013) .
A population growth rate was defined, as was a rate for newly diagnosed patients, to calculate the number of new patients to enter the second and the third year of the model. Another relevant data used for the population progression were the 'failure' rate to treatment, defining the percentage of non-responder patients who changed intravitreal therapies during the 3 years (deriving from administrative records of the patients taken in charge by the hospitals).
Once the population had been defined, the market shares of the technologies under investigation were identified considering the average drugs consumption rate, consistent with the three hospitals clinical practice (years 2014-2015) , thus leading to different scenarios.
Budget impact model and scenarios development
The BIA design was dependent on: (i) the development of the population entering the model (point 1); (ii) the scenarios taken into account for the forecasts of the economic burden (point 2); and (iii) the economic evaluation related to the DME patient's pathway (point 3).
The baseline scenario (Scenario 1), consisting of Ranibizumab intravitreal injections, was compared with various different innovative scenarios (Fig. 1 ).
• Scenario 2: Dexamethasone administered as a second-line therapy to patients 'non-responder' to a previous treatment with Ranibizumab, or to patients not eligible for anti-VEGF therapy.
• Scenario 3 and Scenario 4: Dexamethasone introduced both as a firstline and second-line alternative to Ranibizumab. Two such scenarios were created, with differing nonresponder rates to Ranibizumab.
• A further two additional scenarios were created and compared with Scenario 3 to assess whether any significant changes in DME healthcare expenditure occurred with the inclusion of Aflibercept, either as a second-line only option for corticosteroid non-responder patients (scenario 5), or when used as a first-line alternative to Ranibizumab as well as a second-line treatment option to Dexamethasone (scenario 6).
• Finally, the predicted budget impact was calculated when switching from the treatment frequency declared by the hospitals as their real-life utilisation to the retreatment rates derived from the clinical trials where an average of 14 intravitreal injections of anti-VEGF (Mitchell et al. 2011; Korobelnik et al. 2014) or an average of four Dexamethasone implants (Boyer et al. 2014) were administered over a 36-month time horizon. Hence Scenarios 3 and 6 above were compared with the Scenarios 7 and 8 (maintaining the same market shares but applying the retreatment rates derived from the clinical trials).
• The final scenarios were performed to ascertain the impact of implementing a market share based on the rates of pseudophakic patients (25%) and injection rates from the Dexamethasone registration study (Boyer et al. 2014 ): scenario 9 using real-life retreatment rates and scenario 10 with clinical trial retreatment rates. e469
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Economic evaluation of the DME patient's pathway
The economic impact of a patient receiving DME treatment was determined utilising the following components.
• Drug costs, based on the injection frequency utilised in the three hospitals of reference.
• Non-drug therapy-related costs, including diagnostic tests [optical coherence tomography (OCT) and fluorescein angiography], specialist visits and the procedure costs for the intravitreal injections (the tariff reimbursed for the Italian outpatient procedure -which consists of the ophthalmological visit before and after the intravitreal injection as well as the actual injection itself -was considered).
• Cost of managing side-effects (laboratory tests, diagnostic and surgical procedures, clinician visits and hospital admissions), depending on the incidence and therapeutic strategy administered, retrieved from the literature for Ranibizumab (Mitchell et al. 2011) , Dexamethasone (Boyer et al. 2014) and Aflibercept (Korobelnik et al. 2014 ).
The economic analysis was performed with time horizons of 12, 24 and 36 months and utilised the 2015 Lombardy Region's outpatients and hospital admissions Reimbursement Tariffs. Drug costs were derived from the officially published NHS price list.
With regard to the injection frequency and the additional procedures related to the DME treatment and the management of side-effects, data from the standard clinical pathways (for the years 2014-2015) carried out in the three hospitals involved were used, which was fine-tuned with the support of the clinicians of reference approaching with a Delphi methodology (Quinn Patton 2002) .
It should be noted here that, even though the fourth drug (bevacizumab) is not included in the BIA, the related entire process cost will be described to give a complete picture of the possible alternative DME treatments, to be chosen by the clinicians of reference.
Results
The reference population: demographic inputs of the BIA The total number of patients eligible for treatment was estimated by applying the diabetes and DME prevalence rates to the Lombardy population (Diabetic Retinopathy Guidelines, 2013) . Table 1 shows that an estimated 36 780 individuals had DME in the Lombardy Region in 2014. Only 15% of these were considered likely to receive intravitreal injections, as not all diagnosed patients require (or are eligible for) intravitreal therapy, and a significant proportion of other patients remain undiagnosed and therefore do not have access to treatment.
The treatable population was assumed to grow at a year-on-year rate of +15.19%, as evidenced by the administrative records of the hospitals involved.
Once the target population number had been established, various market share assumptions (derived from the clinical practices performed in the hospitals) for Ranibizumab, Dexamethasone and Aflibercept intravitreal treatments were applied as determined in the scenario descriptions, as shown in Table 2 .
The economic evaluation of the patients with DME pathway: economic inputs of the BIA The average number of injections administered to each patient during the first year of therapy was 3.61, 2.61 and 4.2, respectively for Ranibizumab, Dexamethasone and Aflibercept, whilst the second and the third years were characterised by 3.84 Ranibizumab injections, 1.3 Dexamethasone injections and 3.3 Aflibercept injections per year. The same trend as Aflibercept was hypothesised with regard to Bevacizumab. The drug was administered on average every three/four months.
Despite the above-mentioned information regarding the treatment frequency is low with respect to the clinical trials, they are consistent with the clinical utilisation of the drugs in the real-life practice (Kiss et al. 2014) .
The drug and procedure-related costs for a single injection were €934.73 for Ranibizumab, €1212.42 for Dexamethasone, €971.43 for Aflibercept and €350.00 for Bevacizumab. When these costs were multiplied by the average number of injections per patient, and the costs of the additional procedures, such as OCT (range: 3.2-8), fluorescein angiography (range: 1-2.6) and ophthalmologic visits (range: 2-6.8) required for the proper management of the patients were added, the average cost per patient with DME was determined. Within the first year of treatment, the average economic absorption was equal to €3740.08, €3521.44 €4276.60 and €1562.25 considering Ranibizumab, Dexamethasone, Aflibercept and Bevacizumab, respectively. Both in a 24-month and in a 36-month time period, the average cost for the management of a patient with DME was 
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.27 (Ranibizumab), €1760.72 (Dexamethasone), €3347.01 (Aflibercept) and €1272.15 (Bevacizumab). As a result, it emerged that the cumulative economic resource absorption for a patient remaining in treatment for 3 years amounted to €11 500.62 for Ranibizumab, €7042.87 for Dexamethasone and €10 970.62 for Aflibercept, thus resulting in an incremental cost (+63.29% and +55.77%, respectively) of anti-VEGF administration with respect to the corticosteroid implant, considering the approved drugs. If Bevacizumab were approved, and if in real clinical practice it was administered with a frequency similar to that seen with the currently licensed anti-VEGF agents (i.e. with a lower number of reinjections per year compared with the clinical trials), it would be the least expensive drug over a 36-month time horizon, with an economic benefit (per patient) ranging from a minimum of À41.69% (if compared with Dexamethasone) to a maximum of À62.57%/À64.29% (if compared with Aflibercept and Ranibizumab, respectively). The cost difference compared with Dexamethasone implant would narrow significantly if it were used more in line with clinical trial protocols such as the recently published Protocol T (Wells et al. 2015) .
Finally, to complete the economic analysis for the BIA, the costs relating to the management of drug-related adverse events were determined and applied. The most common side-effects, the related incidence rates and the economic evaluations, are presented in Table 3 and derived from the drugrelated clinical trials. The introduction of Dexamethasone intravitreal implant in the Lombardy Region would result in significant economic savings, from a minimum of À4.35% (should the corticosteroid be used only as a second-line treatment), to a maximum of À12.97% (when used as a first-and second-line option, and when the non-responder rate for Ranibizumab is equal to 30%) over 36 months. Scenarios 2, 3, 4 and 9 demonstrated that as the use of Dexamethasone increased, the economic advantage for the LRHS became progressively greater.
Results from the budget impact analysis
The inclusion of Aflibercept as a second-line treatment option only (scenario 5) or as a first-and second-line option (scenario 6) was predicted to have minimal impact on the overall Lombardy Region healthcare expenditure (+0.12% and À0.89%, respectively), over the course of the 36 months studied.
The model demonstrated that applying the retreatment rates used in the clinical trials would require additional investments by the healthcare system, varying from 14.73% (the scenario with a higher use of Dexamethasone) to 22.27%.
Discussion
During recent years, treatment with intravitreal Ranibizumab has significantly changed the management of DME. Whilst this has led to an increase in drug costs (as previously there were no licensed pharmacological treatment options), reduced numbers of patients with visual impairment will produce savings for the health service, social services and for out-of-pocket expenses relating to personal assistance.
This evidence-based analysis provides useful information for clinicians and policy makers considering which therapy options to make available and when allocating resources to the different alternatives, and can assist in developing a robust economic forecast which is of prime importance in national and international contexts of limited resources.
The results of this study demonstrate that concentrating all eligible patients within the Ranibizumab regimen is unlikely to represent a cost-effective strategy. Indeed, significant economic advantages would be achieved by introducing the other licensed alternatives, Dexamethasone implant and Aflibercept, thus optimising DME Italian healthcare expenditure. Literature crystallized the above-mentioned result also in other relevant maculopathies (Elias et al. 2015) , suggesting that the final benefit could be more relevant if the same cost-saving strategies are implemented also for the treatment of the overall eye diseases.
The analysis demonstrated that in a clinical setting characterised by the potential administration of all the three options licensed for the treatment of DME currently available, it emerged that: (i) treating a larger proportion of eligible patients with Dexamethasone implant would significantly reduce the healthcare expenditure, and/or free up resources to treat more patients; (ii) the preferable scenario for the regional healthcare service is that which supports patient access to a broad range of alternative technologies as first-choice treatment, which also coincides with maximising clinician choice; (iii) from the comparison between real life and clinical trial retreatment rates, a significant initial investment (within the 12-24 month-time window) would be required, even if could be amply rewarded in the long run (reporting on average the highest value of cost saving in the third year); (iv) the additional investments required to guarantee the retreatment rates used in the clinical trials could be mitigated by applying a higher market share of Dexamethasone, and (v) the inclusion of Aflibercept, both in second-line and in first-line treatment, resulted in a minimal economic impact for the healthcare service. 540 095 DME prevalence rate 6.81% Lombardy Region population suffering from DME 36 780 % of DME potentially treated (expert opinion)
15.00% Lombardy Region Population potentially treated 5517* * The BIA assumed 5517 patients suffering from DME, considering a single-eye treatment.
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Scenario 1 (Baseline, with real-life retreatment rates) Ranibizumab 95% Ranibizumab + Laser 5% Scenario 2 (real-life retreatment rates) Ranibizumab (1st line) 95% Ranibizumab + Laser (1st line) 5% Non-responder patients, switching from Ranibizumab to Dexamethasone (2nd-line DEX) 20% Non-responder patients, switching from Dexamethasone to 6.6% Scenarios 3 (real-life retreatment rates) and 7 (retreatment rates from clinical trials) Ranibizumab (1st line) 80% Dexamethasone (1st line) 20% Non-responder patients, switching from Ranibizumab to Dexamethasone (2nd-line DEX) 20% Non-responder patients, switching Dexamethasone to Ranibizumab (2nd-line Ranibizumab) 6.6% Scenario 4 (real-life retreatment rates) Ranibizumab (1st line) 80% Dexamethasone (1st line) 20% Non-responder patients, switching from Ranibizumab to Dexamethasone (2nd-line DEX) 30% Non-responder patients, switching from Dexamethasone to Ranibizumab (2nd-line Ranibizumab) 6.6% Scenario 5 (real-life retreatment rates) Ranibizumab (1st line) 80% Dexamethasone (1st line) 20% Non-responder patients, switching from Ranibizumab to Dexamethasone (2nd-line DEX) 20% Non-responder patients to Dexamethasone, of whom:
6.6% non-responder patients, switching from Dexamethasone to Ranibizumab (2nd-line Ranibizumab) 50% non-responder patients, switching from Dexamethasone to Aflibercept (2nd-line Aflibercept) 50% Scenarios 6 (real-life retreatment rates) and 8 (retreatment rates from clinical trials) Ranibizumab (1st line) 68% Dexamethasone (1st line) 20% Aflibercept (1st line) 12% Non-responder patients, switching from Ranibizumab to Dexamethasone (2nd-line DEX) 20% Non-responder patients, switching from Aflibercept to Dexamethasone (2nd-line DEX) 20% Non-responder patients to Dexamethasone, of whom:
6.6% non-responder patients, switching from Dexamethasone to Ranibizumab (2nd-line Ranibizumab) 50% non-responder patients, switching from Dexamethasone to Aflibercept (2nd-line Aflibercept) 50% Scenarios 9 (real-life retreatment rates) and 10 (retreatment rates from clinical trials) Ranibizumab (1st line) 63% Dexamethasone (1st line) 25% Aflibercept (1st line) 12% Non-responder patients, switching from Ranibizumab to Dexamethasone (2nd-line DEX) 20% Non-responder patients, switching from Aflibercept to Dexamethasone (2nd-line DEX) 20% Non-responder patients to Dexamethasone, of whom:
6.6% non-responder patients, switching from Dexamethasone to Ranibizumab (2nd-line Ranibizumab) 50% non-responder patients, switching from Dexamethasone to Aflibercept (2nd-line Aflibercept) 50% The results of the presented economic analysis undertaken in the Italian setting are consistent with those published in the other European Countries (UK and Greece), from a healthcare decision maker's perspective, for the treatment of patients with DME (Regnier et al. 2015; Kourlaba et al. 2016; Romero-Aroca et al. 2016) . The economic savings resulting from the adoption of Dexamethasone could be reinvested within the same therapeutic area, thus (i) improving patient access and adherence to therapy, (ii) treating a wider population and (iii) reducing waiting lists. A potential limitation of the study is related to the fact that the model did not take into account another of the anti-VEGF molecules, Bevacizumab, which represents an off-label drug, and by law it can only be implemented, after treatment with label drugs, if those drugs are not effective. The data collected from the centres involved demonstrated that Bevacizumab injections were not used in clinical practice for the management of DME. Moreover, Bevacizumab is reimbursed by the Italian NHS only for wet agerelated degeneration.
The approach to Bevacizumab use is different worldwide: recently, US literature (Wells et al. 2015; McCarthy 2016; Ross et al. 2016 ) declared that, Bevacizumab would represent also a valid first-line treatment option for DME, thus being a cost-saving therapy compared with the other agents.
Besides all the economic information here reported, the results suggest the importance of an adequate stratification of the population suffering from DME, on the basis of the proper treatment regimen according to the specific drugs' indications. This process, concerning the population stratification, could optimise the clinician drugs choice and their correct use, with a positive impact from an economic point of view, thus implementing all the DME technological alternatives available.
Further useful information for decision makers could be obtained by expanding the evaluation to consider not only the economic impact of the alternative technologies as presented here, but also the other dimensions and indicators as required by a multidimensional approach (EUnetHTA, 2015) . This additional perspective could demonstrate further significant differences between treatment options that could be useful for treating patients with DME, thus considering organizational, ethical and social aspects.
